USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: NAPROGENIX, INC
Address: KTRDC - U.K. - AgTecc Laboratories
Lexington, KY 40546-0236
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $422,371.00 2
SBIR Phase II $1,019,366.00 1
STTR Phase I $1,539,472.00 5
STTR Phase II $2,062,628.00 3

Award List:

Application of plant genomics to alcoholic brain damage

Award Year / Program / Phase: 2004 / STTR / Phase I
Agency: HHS
Research Institution: UNIVERSITY OF KENTUCKY
Principal Investigator: John M. Littleton
Award Amount: $97,370.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Alcoholic liver damage (ALD) is among the ten most common causes of death in the USA. The liver may be uniquely sensitive because it metabolizes ethanol at a high rate. This generates acetaldehyde intracellularly, damaging cell components directly, and/or… More

Selection-driven plant metabolites for treatment of CNS diseases

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: John M. Littleton
Award Amount: $272,674.00
Abstract:
DESCRIPTION (provided by applicant): The primary aim is to transfer a biotechnology platform for plant drug discovery from the academic laboratory to industry use (i.e. this application is directly responsive to the lab to marketplace roadmap program). M any defensive metabolites in plants are… More

Novel estrogen receptor ligands from plant genomics

Award Year / Program / Phase: 2010 / STTR / Phase II
Agency: HHS
Research Institution: University Of Kentucky
Principal Investigator: John M. Littleton – 859-257-1085
Award Amount: $699,216.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Human nuclear receptor (HNR) ligands have potential value as pharmacotherapies or chemopreventive agents for many hormone-responsive cancers. The primary aim of this STTR is to transfer an academic plant genomics technology into drug discovery, targeting HNR… More

NOVEL PHARMACOTHERAPIES FOR ALCOHOLISM, TOPIC #4409/24/2012 - 03/23/2013

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: John Littleton – 859-257-1127
Award Amount: $149,697.00
Abstract:
Alcoholism is a complex condition in which there are many potential molecular and therapeutic targets for pharmacotherapy. This fast track SBIR contract aims to investigate compounds targeted on the glutamate/NMDA receptor (NMDAR) and the nicotinic receptor for acetylcholine (nicAChR). These… More

Selection-driven plant metabolites for treatment of CNS diseases

Award Year / Program / Phase: 2013 / SBIR / Phase II
Agency: HHS
Principal Investigator: John M. Littleton – 859-257-1085
Award Amount: $1,019,366.00
Abstract:
DESCRIPTION (provided by applicant): This project aims to demonstrate that the evolution of plant biosynthetic pathways can be accelerated and driven to favor the synthesis of ligands which interact with a specific human target protein. This is achieved bysubjecting mutant plant cells to selection… More